PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE

100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:


Scientific evidence for clinical utility.

By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrintยฎ and BluePrintยฎ test suite.

Evidence

SABCS 2019: Cyclin E Expression

AUTHORS: Lorenza Mittempergher, Joseph McKelley, Rajith Bhaskaran, Sahra Uygun, Reneฬ Bernards, Laura J van โ€™t Veer, Annuska M Glas, Cynthia X Ma, William Audeh DESCRIPTION: Cyclin E overexpression is associated with High Risk 70-gene signature, and may indicate intrinsic resistance to CDK4/6 inhibitors The use of CDK4/6 inhibitors (CDK4/6i) is Read More

SABCS 2019: FLEX Trials in Progress

AUTHORS: Jennifer Crozier, Gordan Srkalovic, Adam Brufsky, Mehran Habibi, Pat Whitworth, Charles Cox6, Ian Grady, Thomas Lomis, Nina Dโ€™Abreo, Sarah Untch1, Erin Yoder, Heather M. Kling, William Audeh, Bastiaan van der Baan, FLEX Investigators Group DESCRIPTION: The FLEX Real World Data Platform Explores New Gene Expression Profiles and Investigator-Initiated Protocols Read More

SABCS 2019: Chinese Patient Clinical Data

AUTHORS: Ava Kwong, Sarah Untch, Heather M. Kling, Christine Finn, William Audeh, Vivian Shin, Sherene Ishtihar, Margaret Chen DESCRIPTION: Different MammaPrint and BluePrint molecular profiles and clinical-pathological features of early stage breast cancer in Chinese patients in the United States and Hong Kong Breast cancer rates among Asian women are Read More

SABCS 2019: FLEX African American Clinical Data

AUTHORS: Raquel Nunes, Dipali Sharma, Lisa E. Blumencranz, Heather M. Kling, Sahra Uygun, Andrea Menicucci, Amy Truitt, Sarah Untch, Jennifer A. Crozier, William Audeh DESCRIPTION: Racial disparities in breast cancer: identifying predisposing clinical and molecular features associated with African American patients Breast cancer (BC) mortality is higher in African-American women Read More

SABCS 2019: PROMIS Clinical Risk

AUTHORS: Michaela Tsai, Hatem Soliman, Shelly Lo, Rubina Qamar, Raye Budway, Ellis Levine, Pat Whitworth, Blanche Mavromatis, Robin Zon, Sarah Untch1, Lisa Blumencranz, Joseph McKelley, William Audeh, PROMIS Investigators Group DESCRIPTION: Treatment recommendations in ER+ patients โ‰ค 50 years: comparison of the 21-gene assay and 70-gene signature in the PROMIS Read More

ESMO Sept 30 Successful launch of the MammaPrint and BluePrint NGS

AUTHORS: Leonie JMJ Delahaye, Anke T Witteveen, Mireille HJ Snel1, Tyson Cavness, Bob Chan, Lorenza Mittempergher, Annuska M Glas DESCRIPTION: Successful launch of the MammaPrint and BluePrint NGS kit at decentralized sites Centralized MammaPrint (MP) and BluePrint (BP) microarray-based genomic tests on FFPE RNA were successfully translated to a targeted Read More

ESMO Sept 29 Unravelling the biological characteristics of MammaPrint

AUTHORS Rajith Bhaskaran, Christian J Griffioen, Diedrik Wehkamp, Lorenza Mittempergher and Annuska M Glas DESCRIPTION: Unravelling the biological characteristics of MammaPrint extreme risk subgroups MammaPrintยฎ(MP) is a 70-gene based prognostic assay that stratifies early-stage breast cancer patients into low and high-risk of relapse. Recently, further stratification of the 70-gene risk Read More